Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to wipe out lung cancer before surgery

NCT ID NCT07642024

Not yet recruiting Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 12, 2026 · Last updated Jun 15, 2026 · Updated 2 times

Summary

This study tests whether adding a new drug (BL-B01D1) to standard treatment (osimertinib) before and after surgery helps people with a specific type of lung cancer (EGFR-mutant). About 90 adults with early-stage, operable lung cancer will receive the combo or standard care. The main goal is to see if the tumor shrinks significantly by the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

    Contact

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

    Contact

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

EGFR-MUTATED RESECTABLE NON-SMALL CELL LUNG CANCER